Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine (RILECSU)

Sanofi

Status and phase: Completed; Phase 2

Conditions: Chronic Spontaneous Urticaria

Treatments: Drug: placebo; Drug: rilzabrutinib

Study type: Interventional

Funder types: Industry

Identifiers

NCT05107115

U1111-1263-4226 (Registry Identifier)

DRI17224

2021-002609-93 (EudraCT Number)

Details and patient eligibility

About

The first phase of this study will be a parallel, 12-week treatment, Phase 2, double-blind, 4 arm study to assess the safety and effectiveness of 3 oral doses of SAR444671 (rilzabrutinib), i.e. dose A, B and C, compared with placebo for decreasing the frequency and severity of itch and urticaria in male and female participants aged 18 years inclusive or older with CSU.

After completion of the double-blind phase of the study, participants will be given the option of enrolling in the 40-week open label extension (OLE) phase of the study. Participants will receive open-label rilzabrutinib at dose C (the dose may be modified based on the 12-week safety and efficacy data). Due to the fact that some participants may be receiving rilzabrutinib for the first time, all participants will be monitored at Week 14, Week 16, Week 20, and Week 24. Afterwards, participants will be monitored at Week 36 and Week 52.

Enrollment: 161 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants who have a diagnosis of CSU refractory to H1-AH at the time of randomization
• Diagnosis of CSU ≥3 months prior to screening visit (Visit 1).
• The presence of itch and hives for ≥6 consecutive weeks at any time prior to screening visit (Visit 1) despite the use of H1-AH during this time period.
• Participants using a study defined H1-AH for CSU treatment. For participants on stable doses of non-study-approved H1-AH, investigators may switch participants to an equivalent dose of a study-approved H1-AH maintenance medication.
• Participants who are omalizumab naïve OR omalizumab-incomplete responders.
• Participants must be willing and able to complete a daily symptom e-diary for the duration of the study.
• During the 7 days before randomization: UAS7 ≥16 and ISS7 ≥8.
• Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion criteria

• Clearly defined underlying etiology for CUs other than CSU (main manifestation being physical urticaria).
• Presence of skin morbidities other than CSU that may interfere with the assessment of the study outcomes.
• Participants with active atopic dermatitis (AD).
• Severe concomitant illness(es) that, in the Investigator's judgment, would adversely affect the patient's participation in the study.
• Known or suspected immunodeficiency, or otherwise recurrent infections of abnormal frequency or prolonged duration suggesting an immune compromised status, as judged by the Investigator.
• History of serious infections requiring intravenous (IV) therapy with the potential for recurrence (as judged by the Site Investigator) with less than 4 weeks interval between resolution of serious infection and first dose of study drug, or currently active moderate to severe infection at Screening (Grade 2 or higher), including active coronavirus disease 2019 (COVID-19).
• Live vaccine except Bacille Calmette Guerin-vaccination within 28 days prior to Day 1 or plan to receive one during the trial; Bacille Calmette Guerin-vaccination within 12 months prior to Screening.
• Active malignancy or history of malignancy within 5 years.
• Conditions that may predispose the participant to excessive bleeding
• Any participant with an uncontrolled disease state as judged by the Investigator, such as asthma, psoriasis, or inflammatory bowel disease, etc. that are typically treated with oral or parenteral corticosteroids
• Previous use of a BTK inhibitor.
• Has received any investigational drug (or is currently using an investigational device) within the 30 days before Day 1, or at least 5 times the respective elimination half-life time (whichever is longer).
• Previous exposure to another investigative drug for CSU.
• Positive for human immunodeficiency virus (HIV) antibody test.
• Presence of hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with positive DNA test result at screening or within 3 months prior to the screening visit.
• Positive hepatitis C antibody test result at screening or within 3 months prior to the screening visit.
• Tuberculosis infection.
• Any of significant laboratory abnormalities and ECG findings at the screening visit.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

161 participants in 4 patient groups, including a placebo group

Rilzabrutinib dose A

Experimental group

Description:

dose A

Treatment:

Drug: rilzabrutinib

Rilzabrutinib dose B

Experimental group

Description:

dose B

Treatment:

Drug: rilzabrutinib

Rilzabrutinib dose C

Experimental group

Description:

dose C

Treatment:

Drug: rilzabrutinib

Placebo

Placebo Comparator group

Description:

Matching placebo

Treatment:

Drug: placebo